• Something wrong with this record ?

Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells

T. Sevrin, H. Imoto, S. Robertson, N. Rauch, U. Dyn'ko, K. Koubova, K. Wynne, W. Kolch, OS. Rukhlenko, BN. Kholodenko

. 2024 ; 43 (9) : 114710. [pub] 20240905

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24018865

Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges for targeted clinical interventions due to prevalent KRAS mutations, rendering PDAC resistant to RAF and MEK inhibitors (RAFi and MEKi). In addition, responses to targeted therapies vary between patients. Here, we explored the differential sensitivities of PDAC cell lines to RAFi and MEKi and developed an isogenic pair comprising the most sensitive and resistant PDAC cells. To simulate patient- or tumor-specific variations, we constructed cell-line-specific mechanistic models based on protein expression profiling and differential properties of KRAS mutants. These models predicted synergy between two RAFi with different conformation specificity (type I1⁄2 and type II RAFi) in inhibiting phospho-ERK (ppERK) and reducing PDAC cell viability. This synergy was experimentally validated across all four studied PDAC cell lines. Our findings underscore the need for combination approaches to inhibit the ERK pathway in PDAC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018865
003      
CZ-PrNML
005      
20241024111122.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.celrep.2024.114710 $2 doi
035    __
$a (PubMed)39240715
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sevrin, Thomas $u Systems Biology Ireland, University College Dublin, Dublin, Ireland
245    10
$a Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells / $c T. Sevrin, H. Imoto, S. Robertson, N. Rauch, U. Dyn'ko, K. Koubova, K. Wynne, W. Kolch, OS. Rukhlenko, BN. Kholodenko
520    9_
$a Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges for targeted clinical interventions due to prevalent KRAS mutations, rendering PDAC resistant to RAF and MEK inhibitors (RAFi and MEKi). In addition, responses to targeted therapies vary between patients. Here, we explored the differential sensitivities of PDAC cell lines to RAFi and MEKi and developed an isogenic pair comprising the most sensitive and resistant PDAC cells. To simulate patient- or tumor-specific variations, we constructed cell-line-specific mechanistic models based on protein expression profiling and differential properties of KRAS mutants. These models predicted synergy between two RAFi with different conformation specificity (type I1⁄2 and type II RAFi) in inhibiting phospho-ERK (ppERK) and reducing PDAC cell viability. This synergy was experimentally validated across all four studied PDAC cell lines. Our findings underscore the need for combination approaches to inhibit the ERK pathway in PDAC.
650    _2
$a lidé $7 D006801
650    12
$a nádory slinivky břišní $x patologie $x farmakoterapie $x metabolismus $7 D010190
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a MAP kinasový signální systém $x účinky léků $7 D020935
650    12
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    12
$a duktální karcinom slinivky břišní $x farmakoterapie $x patologie $x metabolismus $7 D021441
650    _2
$a synergismus léků $7 D004357
650    _2
$a protoonkogenní proteiny p21(ras) $x metabolismus $x genetika $7 D016283
650    _2
$a raf kinasy $x metabolismus $x antagonisté a inhibitory $7 D048490
655    _2
$a časopisecké články $7 D016428
700    1_
$a Imoto, Hiroaki $u Systems Biology Ireland, University College Dublin, Dublin, Ireland
700    1_
$a Robertson, Sarah $u Systems Biology Ireland, University College Dublin, Dublin, Ireland
700    1_
$a Rauch, Nora $u Systems Biology Ireland, University College Dublin, Dublin, Ireland
700    1_
$a Dyn'ko, Uscinnia $u Systems Biology Ireland, University College Dublin, Dublin, Ireland
700    1_
$a Koubova, Katerina $u Systems Biology Ireland, University College Dublin, Dublin, Ireland; Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic
700    1_
$a Wynne, Kieran $u Systems Biology Ireland, University College Dublin, Dublin, Ireland
700    1_
$a Kolch, Walter $u Systems Biology Ireland, University College Dublin, Dublin, Ireland; Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland; School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
700    1_
$a Rukhlenko, Oleksii S $u Systems Biology Ireland, University College Dublin, Dublin, Ireland. Electronic address: oleksii.rukhlenko@ucd.ie
700    1_
$a Kholodenko, Boris N $u Systems Biology Ireland, University College Dublin, Dublin, Ireland; Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland; School of Medicine and Medical Science, University College Dublin, Dublin, Ireland; Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA. Electronic address: boris.kholodenko@ucd.ie
773    0_
$w MED00188029 $t Cell reports $x 2211-1247 $g Roč. 43, č. 9 (2024), s. 114710
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39240715 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111115 $b ABA008
999    __
$a ok $b bmc $g 2201621 $s 1230838
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 43 $c 9 $d 114710 $e 20240905 $i 2211-1247 $m Cell reports $n Cell Rep $x MED00188029
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options